Macroprolactinemia in Patients with Prolactinomas: Prevalence and Clinical Significance

Abstract

Background:

Data on the prevalence of macroprolactinemia in patients with prolactinomas is quite limited as the presence of high-molecular prolactin forms is suspected mainly in subjects with mild hyperprolactinemia and negative pituitary imaging.

Objective:

The main objective of this observational case-control study was to assess the prevalence and clinical significance of macroprolactinemia among patients with prolactinomas.

Methods:

The study population consisted of 239 subjects: 131 prolactinoma patients and 108 sex-, age- and ethnicity– matched healthy controls. Macroprolactinemia was defined by a PRL recovery after PEG precipitation of<40%.

Results:

The prevalence of macroprolactinemia among newly diagnosed prolactinoma patients did not differ statistically from the prevalence in the control group (3.5 vs. 3.7%; p=1.000) but was lower although non-significantly than the subgroup of patients treated with dopamine agonists (DA) (3.5 vs.10.8%; p=0.072). Significant association between disruptions of ovarian function and serum levels of the monomeric as well as high-molecular prolactin isoform was found.

Conclusions:

In few cases, the presence of typical hyperprolactinemia-related clinical symptoms and their disappearance after treatment with DA suggests biological activity of macroprolactin comparable with that of monomeric prolactin isoform. Decrease of macroprolactin levels after DA treatment could suggest tumoral origin of the high-molecular isoform in these rare cases. Although macroprolactinemia is considered a benign condition, pituitary imaging, DA treatment, and prolonged follow-up may be necessary in certain cases. An individualized approach to the management of patients with macroprolactinemia should be applied.

Key words

macroprolactinemia - PEG-precipitation test - prolactinoma

• References

• 1 Suh HK, Frantz AG. Size heterogeneity of human prolactin in plasma and pituitary extracts. J Clin Endocrinol Metab 1974; 39: 928-935
• 2 Fraser IS, Lun ZG, Zhou JP et al. Detailed assessment of big big prolactin in women with hyperprolactinemia and normal ovarian function. J Clin Endocrinol Metab 1989; 69: 585-592
• 3 Jackson RD, Malarkey WB. Sequential prolactin evaluation of a “cured” patient with recurrence of prolactinoma. Am J Med 1987; 82: 343-346
• 4 Olukoga AO, Kane JW. Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition. Clin Endocrinol (Oxf) 1999; 51: 119-126
• 5 Wallace IR, Satti N, Courtney CH et al. Ten-year clinical follow-up of a cohort of 51 patients with macroprolactinemia establishes it as a benign variant. J Clin Endocrinol Metab 2010; 95: 3268-3271
• 6 Alfonso A, Rieniets KI, Vigersky RA. Incidence and clinical significance of elevated macroprolactin levels in patients with hyperprolactinemia. Endocr Pract 2006; 12: 275-280
• 7 Can M, Guven B, Atmaca H et al. Clinical characterization of patients with macroprolactinemia and monomeric hyperprolactinemia. Kaohsiung J Med Sci 2011; 27: 173-176
• 8 Isik S, Berker D, Tutuncu YA et al. Clinical and radiological findings in macroprolactinemia. Endocrine 2012; 41: 327-333
• 9 Lakatos G, Szucs N, Kender Z et al. Macroprolactinemia associated with pituitary macroadenoma: treatment with quinagolide. Orv Hetil 2010; 151: 1072-1075
• 10 Vilar L, Naves LA, Freitas MC et al. Clinical and laboratory features greatly overlap in patients with macroprolactinemia or monomeric hyperprolactinemia. Minerva Endocrinol 2007; 32: 79-86
• 11 Theunissen C, De Schepper J, Schiettecatte J et al. Macroprolactinemia: clinical significance and characterization of the condition. Acta Clin Belg 2005; 60: 190-197
• 12 Tamer G, Telci A, Mert M et al. Prevalence of pituitary adenomas in macroprolactinemic patients may be higher than it is presumed. Endocrine 2012; 41: 138-143
• 13 Anaforoglu I, Ertorer ME, Kozanoglu I et al. Macroprolactinemia, like hyperprolactinemia, may promote platelet activation. Endocrine 2010; 37: 294-300
• 14 Gibney J, Smith TP, McKenna TJ. The impact on clinical practice of routine screening for macroprolactin. J Clin Endocrinol Metab 2005; 90: 3927-3932
• 15 Hattori N. Macroprolactinemia: a new cause of hyperprolactinemia. New Research on Autoantibodies. In: Petrelli CT. Ed Chapter I Nova Science Publishers Inc.; NewYork: 2008: 13-60
• 16 Leslie H, Courtney CH, Bell PM et al. Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method. J Clin Endocrinol Metab 2001; 86: 2743-2746
• 17 Sanchez-Eixeres MR, Mauri M, Alfayate R et al. Prevalence of macroprolactin detected by Elecsys 2010. Horm Res. 2001 56. 87-92
• 18 Suliman AM, Smith TP, Gibney J et al. Frequent misdiagnosis and mismanagement of hyperprolactinemic patients before the introduction of macroprolactin screening: application of a new strict laboratory definition of macroprolactinemia. Clin Chem 2003; 49: 1504-1509
• 19 Vallette-Kasic S, Morange-Ramos I, Selim A et al. Macroprolactinemia revisited: a study on 106 patients. J Clin Endocrinol Metab 2002; 87: 581-588
• 20 Leite V, Cosby H, Sobrinho LG et al. Characterization of big, big prolactin in patients with hyperprolactinaemia. Clin Endocrinol (Oxf) 1992; 37: 365-372
• 21 Sapin R, Gasser F, Grucker D. Free prolactin determinations in hyperprolactinemic men with suspicion of macroprolactinemia. Clin Chim Acta 2002; 316: 33-41
• 22 Hattori N, Ishihara T, Saiki Y. Macroprolactinaemia: prevalence and aetiologies in a large group of hospital workers. Clin Endocrinol (Oxf) 2009; 71: 702-708
• 23 Casanueva FF, Molitch ME, Schlechte JA et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006; 65: 265-273
• 24 Melmed S, Casanueva FF, Hoffman AR et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 273-288
• 25 McCudden CR, Sharpless L, Crenache DG. Comparison of multiple methods for identification of hyperprolactinemiain the presenceo f macroprolactin. Clin Chim Acta 2010; 411 : 55-60
• 26 Mounier C, Trouillas J, Claustrat B et al. Macroprolactinaemia associated with prolactin adenoma. Hum Reprod 2003; 18: 853-857
• 27 Bouchard P, Lagoguey M, Brailly S et al. Gonadotropin-releasing hormone pulsatile administration restores luteinizing hormone pulsatility and normal testosterone levels in males with hyperprolactinemia. J Clin Endocrinol Metab 1985; 60: 258-262
• 28 Sartorio A, Pizzocaro A, Liberati D et al. Abnormal LH pulsatility in women with hyperprolactinaemic amenorrhoea normalizes after bromocriptine treatment: deconvolution-based assessment. Clin Endocrinol (Oxf) 2000; 52: 703-712
• 29 Sauder SE, Frager M, Case GD et al. Abnormal patterns of pulsatile luteinizing hormone secretion in women with hyperprolactinemia and amenorrhea: responses to bromocriptine. J Clin Endocrinol Metab 1984; 59: 941-948
• 30 Hattori N, Ikekubo K, Ishihara T et al. Correlation of the antibody titers with serum prolactin levels and their clinical course in patients with anti-prolactin autoantibody. European Journal of Endocrinology 1994; 130: 438-445
• 31 Schiettecatte J, De Schepper J, Velkeniers B et al. Rapid detection of macroprolactin in the form of prolactin-immunoglobulin G complexes by immunoprecipitation with anti-human IgG-agarose. Clin Chem Lab Med 2001; 39: 1244-1248
• 32 De Schepper J, Schiettecatte J, Velkeniers B et al. Clinical and biological characterization of macroprolactinemia with and without prolactin-IgG complexes. Eur J Endocrinol 2003; 149: 201-207
• 33 Sinha YN. Structural variants of prolactin: occurrence and physiological significance. Endocr Rev 1995; 16: 354-369
• 34 Tanaka T, Yano H, Umezawa S et al. Heterogeneity of big-big hPRL in hyperprolactinemia. Horm Metab Res 1989; 21: 84-88
• 35 Ohnami S, Eto S, Soejima T et al. Characterization of “big big prolactin” in serum and tumor extract in patients with PRL-secreting tumor. Endocrinol Jpn 1987; 34: 325-334